(Q34057795)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

review article

1 reference

title

Peptide analogs in the therapy of prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

author name string

A M Comaru-Schally

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

A Plonowski

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

A Nagy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

G Halmos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

Z Rekasi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

158-166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

Future prospects in prostate cancer

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Evaluation and management of the man who has failed primary curative therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Hormone-refractory (D3) prostate cancer: refining the concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers

21 January 2018

0 references

Bombesin stimulates growth of human prostatic cancer cells in vitro

0 references

Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents

0 references

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

0 references

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

0 references

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

0 references

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

0 references

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

0 references

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

0 references

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

0 references

Identifiers

DOI

10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11027415 AND SRC:MED&resulttype=core&format=json

1 November 2019

1 reference